Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer

Lung Cancer

Volumn 90, Issue 1, 2015, Pages 71-77

  Narita, Yusuke ^a   Matsushima, Yukiko ^a   Shiroiwa, Takeru ^b   Chiba, Koji ^c   Nakanishi, Yoichi ^d   Kurokawa, Tatsuo ^a   Urushihara, Hisashi ^a  

^a KEIO UNIVERSITY   (Japan)

^b National Institute of Public Health   (Japan)

^c YOKOHAMA COLLEGE OF PHARMACY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Cost effectiveness analysis; Gefitinib; Individualized medicine; Non small cell lung cancer; Pharmacoeconomics

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GENERIC DRUG; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COST EFFECTIVENESS ANALYSIS; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; GENE MUTATION; GENETIC SCREENING; HAIR LOSS; HEALTH CARE COST; HIDDEN MARKOV MODEL; HUMAN; JAPAN; META ANALYSIS (TOPIC); MULTIPLE CYCLE TREATMENT; MUTATION RATE; NEUTROPENIA; NON SMALL CELL LUNG CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RASH; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; DNA MUTATIONAL ANALYSIS; ECONOMICS; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; LUNG NEOPLASMS; MARKOV CHAIN; MUTATION; PATHOLOGY; PERSONALIZED MEDICINE; PHARMACOECONOMICS; PROCEDURES; YOUNG ADULT;

ADMINISTRATION, INTRAVENOUS; ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DNA MUTATIONAL ANALYSIS; ECONOMICS, PHARMACEUTICAL; HUMANS; JAPAN; LUNG NEOPLASMS; MARKOV CHAINS; MUTATION; PACLITAXEL; PRECISION MEDICINE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 84940958802     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.07.006     Document Type: Article

References (34)

1. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136:E359-E386.
2. The Center for Cancer Control and Information Services Cancer Mortality (1958-2013) 2014, National Cancer Center, Japan.
3. D'Addario G., Fruh M., Reck M., Baumann P., Klepetko W., Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2010, 21(Suppl. 5):v116-v119.
4. Fathi A.T., Brahmer J.R. Chemotherapy for advanced stage non-small cell lung cancer. Semin. Thorac. Cardiovasc. Surg. 2008, 20:210-216.
5. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., Serwatowski P., Gatzemeier U., Digumarti R., Zukin M., Lee J.S., Mellemgaard A., Park K., Patil S., Rolski J., Goksel T., de Marinis F., Simms L., Sugarman K.P., Gandara D. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008, 26:3543-3551.
6. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N. Engl. J. Med. 2002, 346:92-98.
7. Goffin J., Lacchetti C., Ellis P.M., Ung Y.C., Evans W.K. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J. Thorac. Oncol. 2010, 5:260-274.
8. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004, 350:2129-2139.
9. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
10. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Sunpaweravong P., Han B., Margono B., Ichinose Y. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 2009, 361:947-957.
11. Han J.Y., Park K., Kim S.W., Lee D.H., Kim H.Y., Kim H.T., Ahn M.J., Yun T., Ahn J.S., Suh C. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J. Clin. Oncol. 2012, 30:1122-1128.
12. Mitsudomi T., Morita S., Yatabe Y., Negoro S., Okamoto I., Tsurutani J., Seto T., Satouchi M., Tada H., Hirashima T. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 2010, 11:121-128.
13. Maemondo M., Inoue A., Kobayashi K., Sugawara S., Oizumi S., Isobe H., Gemma A., Harada M., Yoshizawa H., Kinoshita I. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 2010, 362:2380-2388.
14. Fukuoka M., Wu Y.L., Thongprasert S., Sunpaweravong P., Leong S.S., Sriuranpong V., Chao T.Y., Nakagawa K., Chu D.T., Saijo N. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol. 2011, 29:2866-2874.
15. Ministry of Health, Labour and Welfare, Summary of Medical Care Expenditure in 2012. 2014, Available from: http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/12/index.html (in Japanese).
16. Mitsudomi T., Kosaka T., Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. Int. J. Clin. Oncol. 2006, 11:190-198.
17. Shiroiwa T., Sung Y.K., Fukuda T., Lang H.C., Bae S.C., Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. Health Econ. 2010, 19:422-437.
18. Research group on economic evaluation for Japanese public medical benefits, Guideline for economic evaluation of healthcare technologies in Japan 2013.
19. Briggs A., Sculpher M., Claxton K. Decision Modelling for Health Economic Evaluation 2006, Oxford University Press. 1st ed.
20. Horai T. Regimens of Chemotherapy for Lung Cancer 2013, Medical View Co., Ltd. 3rd ed.
21. National Health Insurance Drug Price Standard 2012, Jiho, Inc., Tokyo.
22. Social Insurance Research Laboratory Reimbursement Schedule of Social Insurance 2012.
23. Brown T., Boland A., Bagust A., Oyee J., Hockenhull J., Dundar Y., Dickson R., Ramani V.S., Proudlove C. Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technol. Assess. 2010, 14:71-79.
24. Nafees B., Stafford M., Gavriel S., Bhalla S., Watkins J. Health state utilities for non small cell lung cancer. Health Qual. Life Outcomes 2008, 6:84.
25. Fallowfield L.J., Harper P. Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer. Lung Cancer 2005, 48:365-377.
26. Ku G.Y., Haaland B.A., de Lima Lopes G. Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials. Lung Cancer 2011, 74:469-473.
27. Urushihara H., Taketsuna M., Liu Y., Oda E., Nakamura M., Nishiuma S., Maeda R. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PLoS ONE 2012, 7:e53224.
28. The Center for Cancer Control and Information Services Projected Cancer Incidence in 2014 2014, National Cancer Center, Japan.
29. The Center for Cancer Control and Information Services Cancer Statistics in Japan 2014, National Cancer Center, Japan.
30. de Lima Lopes G., Segel J.E., Tan D.S.W., Do Y.K., Mok T., Finkelstein E. A. Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer 2012, 118:1032-1039.
31. Douillard J.Y., Ostoros G., Cobo M., Ciuleanu T., McCormack R., Webster A., Milenkova T. First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study. Br. J. Cancer 2014, 110.1:55-62.
32. Kamae I. A Japanese-style approach to value-based pricing: scientific basis and theoretical potential. Portrait Health Econ. 2014, 73.
33. Ministry of Health, Labor and Welfare Recent Spending for Prescription Drugs in FY2013 2013, Available from: http://www.mhlw.go.jp/topics/medias/year/13/dl/gaiyo_data.pdf (in Japanese).
34. The Japan Lung Cancer Society The Guideline for Treatment of Lung Cancer 2014.